Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Long-Term Deferred Tax (2023)

Day One Biopharmaceuticals (DAWN) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $94.5 million as the latest value for Q4 2023.

  • Quarterly Long-Term Deferred Tax changed N/A to $94.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $94.5 million through Dec 2023, changed N/A year-over-year, with the annual reading at $94.5 million for FY2023, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q4 2023 was $94.5 million at Day One Biopharmaceuticals.
  • The five-year high for Long-Term Deferred Tax was $94.5 million in Q4 2023, with the low at $94.5 million in Q4 2023.